Testing effectiveness (Phase 2)Looking for participantsNCT07483567
What this trial is testing
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Who this might be right for
CLDN18.2 PositivePrimary Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 90